<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Amid the rapidly rising number of people with <z:mp ids='MP_0002055'>diabetes</z:mp> worldwide, the prevalence of <z:e sem="disease" ids="C0011881" disease_type="Disease or Syndrome" abbrv="">diabetic kidney disease</z:e> (DKD) is expected to increase considerably despite available treatments </plain></SENT>
<SENT sid="1" pm="."><plain>Consequently, novel therapeutic agents are urgently needed </plain></SENT>
<SENT sid="2" pm="."><plain>Ruboxistaurin mesylate is a bisindolylmaleimide that specifically inhibits the beta isoform of protein kinase C (PKC) </plain></SENT>
<SENT sid="3" pm="."><plain>In experimental models of DKD, ruboxistaurin normalized glomerular hyperfiltration, decreased urinary albumin excretion, preserved kidney function, and reduced mesangial expansion, <z:hpo ids='HP_0000096'>glomerulosclerosis</z:hpo>, and <z:hpo ids='HP_0005576'>tubulointerstitial fibrosis</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>These beneficial effects of ruboxistaurin, both alone and combined with renin-angiotensin system inhibition, have been observed in a variety of experimental models of DKD </plain></SENT>
<SENT sid="5" pm="."><plain>A phase 2 study of PKC-beta inhibition in persons with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and DKD already treated with angiotensin converting <z:e sem="disease" ids="C0877008" disease_type="Disease or Syndrome" abbrv="">enzyme inhibition</z:e> and/or angiotensin receptor blockade has been conducted </plain></SENT>
<SENT sid="6" pm="."><plain>Addition of ruboxistaurin for 1 year reduced urinary albumin, prevented an increase in urinary transforming growth factor-beta, and stabilized estimated glomerular filtration rate </plain></SENT>
<SENT sid="7" pm="."><plain>Based on secondary analyses of clinical trials in patients with diabetic <z:hpo ids='HP_0000488'>retinopathy</z:hpo> or <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e>, ruboxistaurin appears safe and may also prevent <z:hpo ids='HP_0003674'>onset</z:hpo> of DKD </plain></SENT>
<SENT sid="8" pm="."><plain>PKC-beta inhibition holds promise as a new strategy to improve <z:e sem="disease" ids="C0022658" disease_type="Disease or Syndrome" abbrv="">kidney disease</z:e> outcomes in <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="9" pm="."><plain>Large-scale clinical trials will be required to confirm safety and to validate prospective benefits of ruboxistaurin on relevant clinical endpoints in DKD </plain></SENT>
</text></document>